AR059225A1 - Sal de citrato, proceso de preparacion y su actividad en terapia - Google Patents
Sal de citrato, proceso de preparacion y su actividad en terapiaInfo
- Publication number
- AR059225A1 AR059225A1 ARP070100366A ARP070100366A AR059225A1 AR 059225 A1 AR059225 A1 AR 059225A1 AR P070100366 A ARP070100366 A AR P070100366A AR P070100366 A ARP070100366 A AR P070100366A AR 059225 A1 AR059225 A1 AR 059225A1
- Authority
- AR
- Argentina
- Prior art keywords
- therapy
- activity
- preparation process
- citrate salt
- salt
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 150000001860 citric acid derivatives Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- QIXMKFAORYGAFN-UHFFFAOYSA-N 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile 2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(CC(O)=O)C(O)=O.Oc1[nH]c2ccc(cc2c1-c1ccc(CN2CCOCC2)cn1)C#N QIXMKFAORYGAFN-UHFFFAOYSA-N 0.000 abstract 1
- 102000001267 GSK3 Human genes 0.000 abstract 1
- 108060006662 GSK3 Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76455106P | 2006-02-02 | 2006-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059225A1 true AR059225A1 (es) | 2008-03-19 |
Family
ID=38327680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100366A AR059225A1 (es) | 2006-02-02 | 2007-01-29 | Sal de citrato, proceso de preparacion y su actividad en terapia |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8008294B2 (https=) |
| EP (1) | EP1981869A4 (https=) |
| JP (1) | JP2009525324A (https=) |
| KR (1) | KR20080098022A (https=) |
| CN (2) | CN101379053A (https=) |
| AR (1) | AR059225A1 (https=) |
| AU (1) | AU2007210336B2 (https=) |
| BR (1) | BRPI0706745A2 (https=) |
| CA (1) | CA2641900A1 (https=) |
| EC (1) | ECSP088647A (https=) |
| IL (1) | IL192888A0 (https=) |
| MX (1) | MX2008009719A (https=) |
| MY (1) | MY146102A (https=) |
| NO (1) | NO20083784L (https=) |
| NZ (1) | NZ570849A (https=) |
| PE (1) | PE20090192A1 (https=) |
| RU (1) | RU2415137C2 (https=) |
| SA (1) | SA07280004B1 (https=) |
| SG (1) | SG169381A1 (https=) |
| TW (1) | TW200800977A (https=) |
| UA (1) | UA94251C2 (https=) |
| UY (1) | UY30126A1 (https=) |
| WO (1) | WO2007089191A1 (https=) |
| ZA (1) | ZA200806725B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA07280004B1 (ar) * | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
| BRPI0810216A2 (pt) * | 2007-04-18 | 2014-10-21 | Astrazeneca Ab | Processo para a preparação de composto, composto, e, método de tratamento de distúrbio bipolar |
| CN101772497A (zh) * | 2007-07-30 | 2010-07-07 | 阿斯利康(瑞典)有限公司 | 2-羟基-3-[5-(吗啉-4-基甲基)吡啶-2-基]1h-吲哚-5-腈柠檬酸盐的新结晶形式 |
| US20100189791A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002253432B2 (en) | 2001-04-05 | 2005-03-24 | Torrent Pharmaceuticals Ltd. | Heterocyclic compounds for aging-related and diabetic vascular complications |
| JP2003009588A (ja) | 2001-06-20 | 2003-01-10 | Toshiba Corp | 車両連続運転装置用インバータ装置 |
| SE0302546D0 (sv) | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| JP2007502300A (ja) * | 2003-08-13 | 2007-02-08 | カイロン コーポレイション | Ｇｓｋ−３インヒビターおよびその使用 |
| EP1833819A1 (en) | 2004-12-30 | 2007-09-19 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
| SA07280004B1 (ar) | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
-
2007
- 2007-01-23 SA SA07280004A patent/SA07280004B1/ar unknown
- 2007-01-29 TW TW096103245A patent/TW200800977A/zh unknown
- 2007-01-29 AR ARP070100366A patent/AR059225A1/es not_active Application Discontinuation
- 2007-01-31 CN CNA2007800041531A patent/CN101379053A/zh active Pending
- 2007-01-31 AU AU2007210336A patent/AU2007210336B2/en not_active Ceased
- 2007-01-31 MX MX2008009719A patent/MX2008009719A/es active IP Right Grant
- 2007-01-31 NZ NZ570849A patent/NZ570849A/en not_active IP Right Cessation
- 2007-01-31 MY MYPI20082900A patent/MY146102A/en unknown
- 2007-01-31 RU RU2008131906/04A patent/RU2415137C2/ru not_active IP Right Cessation
- 2007-01-31 BR BRPI0706745-3A patent/BRPI0706745A2/pt not_active IP Right Cessation
- 2007-01-31 US US12/162,540 patent/US8008294B2/en not_active Expired - Fee Related
- 2007-01-31 UA UAA200809265A patent/UA94251C2/ru unknown
- 2007-01-31 CA CA002641900A patent/CA2641900A1/en not_active Abandoned
- 2007-01-31 EP EP07709302A patent/EP1981869A4/en not_active Withdrawn
- 2007-01-31 WO PCT/SE2007/000086 patent/WO2007089191A1/en not_active Ceased
- 2007-01-31 JP JP2008553201A patent/JP2009525324A/ja not_active Ceased
- 2007-01-31 SG SG201100793-7A patent/SG169381A1/en unknown
- 2007-01-31 KR KR1020087019047A patent/KR20080098022A/ko not_active Ceased
- 2007-01-31 UY UY30126A patent/UY30126A1/es not_active Application Discontinuation
- 2007-01-31 CN CNA2007800043630A patent/CN101378754A/zh active Pending
- 2007-02-02 US US11/670,681 patent/US20070203137A1/en not_active Abandoned
- 2007-08-02 PE PE2007001013A patent/PE20090192A1/es not_active Application Discontinuation
-
2008
- 2008-07-17 IL IL192888A patent/IL192888A0/en unknown
- 2008-07-24 EC EC2008008647A patent/ECSP088647A/es unknown
- 2008-08-01 ZA ZA200806725A patent/ZA200806725B/xx unknown
- 2008-09-02 NO NO20083784A patent/NO20083784L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1981869A1 (en) | 2008-10-22 |
| SA07280004B1 (ar) | 2011-10-29 |
| ZA200806725B (en) | 2009-07-29 |
| US20070203137A1 (en) | 2007-08-30 |
| MY146102A (en) | 2012-06-29 |
| AU2007210336A1 (en) | 2007-08-09 |
| BRPI0706745A2 (pt) | 2011-04-05 |
| UA94251C2 (ru) | 2011-04-26 |
| KR20080098022A (ko) | 2008-11-06 |
| CN101379053A (zh) | 2009-03-04 |
| US20090023732A1 (en) | 2009-01-22 |
| PE20090192A1 (es) | 2009-03-20 |
| CN101378754A (zh) | 2009-03-04 |
| WO2007089191A1 (en) | 2007-08-09 |
| UY30126A1 (es) | 2007-09-28 |
| JP2009525324A (ja) | 2009-07-09 |
| US8008294B2 (en) | 2011-08-30 |
| RU2415137C2 (ru) | 2011-03-27 |
| TW200800977A (en) | 2008-01-01 |
| EP1981869A4 (en) | 2010-08-25 |
| CA2641900A1 (en) | 2007-08-09 |
| RU2008131906A (ru) | 2010-03-10 |
| NO20083784L (no) | 2008-10-13 |
| MX2008009719A (es) | 2008-09-04 |
| AU2007210336B2 (en) | 2011-03-24 |
| SG169381A1 (en) | 2011-03-30 |
| ECSP088647A (es) | 2008-08-29 |
| NZ570849A (en) | 2011-01-28 |
| IL192888A0 (en) | 2009-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012003283A2 (pt) | sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente. | |
| DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
| WO2008146178A3 (en) | A novel tablet dosage form | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| MX2009000507A (es) | Espuma farmaceutica de acidos grasos. | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| NO20080220L (no) | Formuleringer med hoy medikament belastning og doseringsformer | |
| BRPI0607762B8 (pt) | análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto | |
| SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
| CO6251364A2 (es) | Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| CL2008000594A1 (es) | Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades. | |
| AR059225A1 (es) | Sal de citrato, proceso de preparacion y su actividad en terapia | |
| BR112014009910A2 (pt) | formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico | |
| Iorizzo et al. | Today's treatments options for onychomycosis | |
| NO20085414L (no) | Farmasoytiske preparater for vedvarende frigivelse av fenylefrin | |
| AR054238A1 (es) | Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona | |
| CO6460763A2 (es) | Métodos y formulaciones ectoparasiticidas | |
| ECSP10010464A (es) | Uso de ranolazina para el tratamiento de enfermedades cardiovasculares | |
| WO2008051527A3 (en) | Sustained release of agents for localized pain management | |
| WO2008041116A3 (en) | Formulations of active principles incorporated in slns suitable for transdermal administration | |
| CR8059A (es) | Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas | |
| WO2007100282A8 (en) | New salts of an indole derivative and their use in medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |